Pivotal Trial of DMD Gene Therapy SRP-9001 Launches Globally

Pivotal Trial of DMD Gene Therapy SRP-9001 Launches Globally

308414

Pivotal Trial of DMD Gene Therapy SRP-9001 Launches Globally

Sarepta Therapeutics and Roche have announced the launch of EMBARK, a pivotal clinical trial testing the investigational gene therapy SRP-9001 in boys with Duchenne muscular dystrophy (DMD). In accordance with previously stated development plans, the trial is set to enroll approximately 75 boys between the ages of 4 and 7 at sites in the U.S., Europe, and Asia. Specific study sites have not yet been announced. “We are delighted to announce the initiation of EMBARK,…

You must be logged in to read/download the full post.